Assessing Financial Difficulty in Patients With Blood Cancers

Date Added
April 16th, 2020
PRO Number
Pro00089787
Researcher
Irl Greenwell

List of Studies


Keywords
Cancer, Cancer/Leukemia, Cancer/Myeloma
Summary

This study is for patients that have been diagnosed with either chronic lymphocytic leukemia, multiple myeloma or both. The purpose of this study is to estimate the proportion of patients with MM and/or CLL who report experiencing financial difficulty in the past 12 months. Participants will complete a telephone survey within 8 weeks after joining the study.

Institution
MUSC
Recruitment Contact
Barbara Roe
843-652-1607
broe@tidelandshealth.org

A PHASE II EVALUATION OF BENDAMUSTINE, OBINUTUZUMAB AND VENETOCLAX IN PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA

Date Added
January 28th, 2020
PRO Number
Pro00095207
Researcher
Irl Greenwell

List of Studies


Keywords
Cancer, Cancer/Lymphoma, Drug Studies, Men's Health, Women's Health
Summary

This study is for adult male and females that have been diagnosed with mantle cell lymphoma. The drugs in this study include the combination of bendamustine, obinutuzumab and venetoclax (also called "BOV"). They are each approved for treatment, but is considered investigational (not approved by the FDA), when combined. The purpose of this study is to find out if BOV is effective and safe for the treatment of people with mantle cell lymphoma. Participants can expect to be in this study for approximately 51/2 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classic Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL)

Date Added
November 26th, 2019
PRO Number
Pro00092170
Researcher
Irl Greenwell

List of Studies


Keywords
Cancer, Cancer/Lymphoma, Drug Studies, Men's Health, Women's Health
Summary

This study is for adult male and female subjects that have been diagnosed with classical Hodgkin lymphoma (cHL) or peripheral T cell lymphoma (PTCL). The investigational drug in this study is Brentuximab vedotin. The purpose of this study is to test if brentuximab vedotin works to treat cHL and PTCL in people who already got brentuximab vedotin. Participants in this study will visit MUSC at least every 21 days and will continue to be followed every 4 months, until the study is closed.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Phase II Study of Palbociclib (PD-0332991) in Combination with Ibrutinib in Patients with Previously Treated Mantle Cell Lymphoma

Date Added
August 27th, 2019
PRO Number
Pro00091524
Researcher
Irl Greenwell

List of Studies


Keywords
Cancer, Cancer/Lymphoma, Drug Studies, Men's Health, Women's Health
Summary

This study is for subjects that have been diagnosed with mantle cell lymphoma (MCL) and have already received at least one form of treatment. This study will evaluate the effects, good and bad, of the study drugs palbociclib and ibrutinib in your type of cancer. The purpose of this study is to study the effects of an investigational combination of ibrutinib and a drug called palbociclib on MCL. The subject will be in the study for as long as you do not experience any unacceptable side effects and your cancer does not become worse.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Date Added
March 12th, 2019
PRO Number
Pro00086655
Researcher
Irl Greenwell

List of Studies


Keywords
Cancer, Cancer/Leukemia
Summary

This study is for patients that have been diagnosed with chronic lymphocytic leukemia (CLL). The investigational drugs in this study are ibrutinib, obinutuzumab and venetoclax. The purpose of this study is to compare the usual treatment of ibrutinib and obinutuzumab to a combination treatment of ibrutinib and obinutuzumab plus the study drug, venetoclax.

Institution
MUSC
Recruitment Contact
Nancy McGaha
864-725-7129
nmcgaha@selfregional.org



-- OR --